Cassava Sciences | PTIE - Equity Capital And Reserves


Cassava Sciences reported $68.14M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Amgen USD 11.69B 2.5B Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
Cara Therapeutics USD 14.5M 6.44M Mar/2026
Cassava Sciences USD 68.14M 6.26M Mar/2026
Eisai JPY 906.56B 7.57B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Geron USD 218.61M 10.49M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Novavax USD -190.71M 45.94M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026